Debbie Robbrecht

700 total citations
49 papers, 369 citations indexed

About

Debbie Robbrecht is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Debbie Robbrecht has authored 49 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 16 papers in Surgery and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Debbie Robbrecht's work include Cancer Immunotherapy and Biomarkers (18 papers), Bladder and Urothelial Cancer Treatments (12 papers) and Urinary and Genital Oncology Studies (11 papers). Debbie Robbrecht is often cited by papers focused on Cancer Immunotherapy and Biomarkers (18 papers), Bladder and Urothelial Cancer Treatments (12 papers) and Urinary and Genital Oncology Studies (11 papers). Debbie Robbrecht collaborates with scholars based in Netherlands, United States and Spain. Debbie Robbrecht's co-authors include Morten Mau‐Sørensen, Martijn P. Lolkema, Neeltje Steeghs, Denis Wulfrank, G Verdonk, Jehad Charo, Ignacio Melero, D Clément, Volker Teichgräber and Christophe Boetsch and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Debbie Robbrecht

45 papers receiving 358 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Debbie Robbrecht Netherlands	11	189	132	119	59	47	49	369
Daniela Bianconi Austria	10	161 0.9×	52 0.4×	100 0.8×	51 0.9×	64 1.4×	23	306
Kunio Iura Japan	11	229 1.2×	159 1.2×	140 1.2×	39 0.7×	218 4.6×	20	456
Franziska Leonhardt Germany	10	58 0.3×	131 1.0×	145 1.2×	45 0.8×	24 0.5×	13	385
Ying L. Liu United States	14	198 1.0×	59 0.4×	104 0.9×	77 1.3×	69 1.5×	48	481
Melinda Vassallo United States	8	227 1.2×	118 0.9×	108 0.9×	58 1.0×	91 1.9×	10	406
Kinji Itoh Japan	8	93 0.5×	119 0.9×	143 1.2×	82 1.4×	115 2.4×	9	415
Sasan Ghaffari Iran	10	123 0.7×	84 0.6×	117 1.0×	30 0.5×	36 0.8×	21	309
Johannes Andel Austria	10	254 1.3×	98 0.7×	95 0.8×	36 0.6×	94 2.0×	30	429
Rosemarie Tremblay‐LeMay Canada	6	127 0.7×	122 0.9×	93 0.8×	40 0.7×	19 0.4×	9	342
Bruno R. Bastos United States	10	130 0.7×	45 0.3×	89 0.7×	93 1.6×	62 1.3×	31	299

Countries citing papers authored by Debbie Robbrecht

Since Specialization

Citations

This map shows the geographic impact of Debbie Robbrecht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debbie Robbrecht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debbie Robbrecht more than expected).

Fields of papers citing papers by Debbie Robbrecht

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debbie Robbrecht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debbie Robbrecht. The network helps show where Debbie Robbrecht may publish in the future.

Co-authorship network of co-authors of Debbie Robbrecht

This figure shows the co-authorship network connecting the top 25 collaborators of Debbie Robbrecht. A scholar is included among the top collaborators of Debbie Robbrecht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debbie Robbrecht. Debbie Robbrecht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Robbrecht, Debbie, John W.M. Martens, Maureen J.B. Aarts, et al.. (2025). Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer—A Patient Cohort Analysis. European Urology Oncology. 9(1). 7–11. 1 indexed citations

Lussanet, Quido G. de, Erik de Blois, Stijn L.W. Koolen, et al.. (2025). First real-world clinical experience with [177Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria. European Journal of Nuclear Medicine and Molecular Imaging. 52(6). 2034–2040. 2 indexed citations

Mehra, Niven, Jens Voortman, David R. Wise, et al.. (2024). Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(16_suppl). TPS2672–TPS2672. 4 indexed citations

Steeghs, Neeltje, Carlos Gomez‐Roca, Kristoffer Staal Rohrberg, et al.. (2024). Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors. Clinical Cancer Research. 30(13). 2693–2701. 11 indexed citations

Ausems, Margreet G.E.M., Lambertus A. Kiemeney, Harm H.E. van Melick, et al.. (2024). Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer. Prostate Cancer and Prostatic Diseases. 28(3). 789–794. 1 indexed citations

Robbrecht, Debbie, Alberto Gil-Jimenez, Hayri E. Balcıoğlu, et al.. (2024). Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer. Nature Communications. 15(1). 1349–1349. 6 indexed citations

Salhi, Yazan Al, Debbie Robbrecht, Ronald de Wit, et al.. (2023). The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial. BMC Cancer. 23(1). 539–539. 1 indexed citations

Robbrecht, Debbie, et al.. (2023). “If only I had”, patients’ experiences during early oncology trials. Supportive Care in Cancer. 31(5). 290–290. 1 indexed citations

Perera, Timothy, Laurence Mévellec, Hans Prenen, et al.. (2023). Abstract C152: Preclinical and emerging Phase 1 study data indicates that novel deuterated MET kinase inhibitor DO-2 mitigates the side effects seen with current approved MET kinase inhibitors: Preventing deleterious ‘de-hinging’ to improve tolerability. Molecular Cancer Therapeutics. 22(12_Supplement). C152–C152. 1 indexed citations

10.

Wit, Ronald de, et al.. (2023). Immunotherapy in Urothelial Cancer: Stop When Achieving a Response, Restart upon Disease Progression. Cancers. 15(14). 3654–3654. 1 indexed citations

11.

Boellaard, Thierry N., Joost L. Boormans, Richard P. Meijer, et al.. (2023). Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial. Frontiers in Oncology. 13. 1246603–1246603. 3 indexed citations

12.

Richters, Anke, Debbie Robbrecht, Richard P. Meijer, et al.. (2023). Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort. European Urology Open Science. 59. 50–54. 1 indexed citations

13.

Robbrecht, Debbie, Ronald de Wit, Vanja de Weerd, et al.. (2022). Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer. Molecular Oncology. 16(10). 2086–2097. 14 indexed citations

14.

Groenendijk, Floris H., Debbie Robbrecht, Winand N.M. Dinjens, et al.. (2022). Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing. British Journal of Cancer. 127(4). 776–783. 3 indexed citations

15.

Robbrecht, Debbie, Mandy van Brakel, Joost L. Boormans, et al.. (2022). A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer. Cancer Immunology Immunotherapy. 72(3). 759–767. 9 indexed citations

16.

Delanoy, Nicolas, Debbie Robbrecht, Mario A. Eisenberger, et al.. (2021). Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study. Cancers. 13(6). 1284–1284. 5 indexed citations

17.

Virtakoivu, Reetta, Jenna H. Rannikko, Miro Viitala, et al.. (2021). Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. Clinical Cancer Research. 27(15). 4205–4220. 41 indexed citations

18.

Hoogstraten, Lisa M.C. van, Lambertus A. Kiemeney, J. Alfred Witjes, et al.. (2021). Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients. World Journal of Urology. 40(1). 111–118. 7 indexed citations

19.

Bono, Petri, Panu Jaakkola, Shishir Shetty, et al.. (2020). 1024MO A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer. Annals of Oncology. 31. S706–S707. 1 indexed citations

20.

Robbrecht, Debbie, Juanita Lopez, Emiliano Calvo, et al.. (2020). A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours. British Journal of Cancer. 124(2). 391–398. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact